All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1800+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Geron's Rytelo (telomerase inhibitor) approved in Europe for treating adults with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes
Oligonucleotide, myelodysplastic syndrome, anemia - Read more

Johnson & Johnson's Monarch Quest, an AI-powered bronchoscopy robot, received FDA clearance for live CT navigation during lung cancer biopsies
CT imaging, AI, bronchoscopy, robotics - Read more

THE GOOD
Business Development

Ono Pharmaceutical pays Ionis Pharmaceuticals $280M upfront for rare blood disease drug sapablursen (targeting TMPRSS6), with potential for $660M more and royalties
Antisense oligonucleotide, polycythemia vera - Read more

PRESENTED BY YOU?
Get the attention of 1800+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials

Merck announced positive Ph3 trial results showing once-daily oral doravirine/islatravir maintained HIV-1 viral suppression at 48 weeks with comparable safety to standard treatments
Small molecule, antiviral, human immunodeficiency virus (HIV) - Read more

ViiV Healthcare (GSK) pursues six-month IV N6LS (targeting CD4bs) therapy with cabotegravir (integrase strand transfer inhibitor) for HIV, following successful Ph2b trial showing 96% viral suppression
Monoclonal antibody, human immunodeficiency virus (HIV) - Read more

QurAlis touts positive Ph1 data for QRL-101 (Kv7 potassium channel opener) in amyotrophic lateral sclerosis and epilepsy
Small molecule, amyotrophic lateral sclerosis (ALS/Lou Gehrig's disease), biomarker, epilepsy - Read more

OSE Immunotherapeutics and GERCOR's cancer vaccine OSE2101 (Tedopi) achieved positive results in Ph2 trial for advanced pancreatic ductal adenocarcinoma
Cancer vaccine, "Off-the-shelf" cancer vaccine, pancreatic cancer - Read more

YolTech Therapeutics touts positive Ph1 data for YOLT-201 gene-editing therapy in ATTR-CM
Gene-editing, in-vivo gene-editing therapy, transthyretin amyloidosis/transthyretin amyloid cardiomyopathy (ATTR-CM), CRISPR - Read more

THE GOOD
Company Launches

Harbour BioMed launches Élancé Therapeutics to develop bispecific antibody therapies for obesity with muscle preservation benefits
Bispecific antibody, obesity, lean mass preservation - Read more

THE GOOD
Fundraises

Insilico Medicine $110M Series E, advancing AI-designed drug portfolio with lead candidate in mid-stage trials
Small molecule, drug discovery, AI, cancer, pulmonary fibrosis, inflammatory bowel disease (IBD) - Read more

Vivace Therapeutics raised $35M Series D to advance VT3989 (targeting TEAD) into Phase III trial for mesothelioma
Small molecule, mesothelioma - Read more

StimOxyGen raised £1.5M ($1.9M) funding, developing nanoparticle-based tech that delivers oxygen to hypoxic tumor environments, enhancing radiotherapy effectiveness
Nanoparticle, tumor oxygenation, cancer - Read more

THE GOOD
Investments

J&J and Legend investing $150M to expand Belgium facility for Carvykti cell therapy production to meet anticipated demand
Cell therapy, cell therapy manufacturing, facility expansion, T cell therapy, cancer - Read more

THE GOOD
Marketing

Celltrion's infliximab (targeting TNF-α) rebranding to Remdantry in Canada from April 2025, maintaining same formulation and indications
Product name change, monoclonal antibody, biosimilar, psoriatic arthritis, rheuma­toid arthri­tis, plaque psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis - Read more

THE GOOD
Mergers & Acquisition

Mallinckrodt and Endo consider $7B merger, potentially combining two opioid crisis-affected drugmakers who recently faced bankruptcy
Opioid, opioid epidemic, M&A strategy - Read more

PharmaCord and Mercalis merge to create a comprehensive biopharmaceutical services platform enhancing patient access and medication support
Commercialization, market access - Read more

NB Renaissance in exclusive talks to acquire Italian pharmaceutical company Genetic SpA for $764M
Small molecule, private equity acquisition - Read more

PerkinElmer acquires Project Farma, expanding OneSource professional services for life sciences customers from ideation through commercialization
Life science consulting - Read more

Tempus AI acquires Deep 6 AI, expanding its provider network to over 750 locations and 30 million patients post-IPO
Clinical trial enrolment, electronic health records, AI - Read more

THE GOOD
Partnerships

Teknova, Pluristyx, collaborating to produce and commercialize PluriFreeze cryopreservation media for allogeneic cell therapies
Cell therapy, cell therapy manufacturing, induced pluripotent stem cell (IPSC/iPS cell), reagents - Read more

Emergent BioSolutions, Rocketvax, undisclosed investment as part of strategic partnership to support Swiss biotech's R&D and portfolio expansion
Vaccine, COVID-19, company creation/building, investment + partnership - Read more

THE GOOD
Research

University of Maryland researchers show meningococcal pentavalent vaccine safe for infants in Africa, leading to WHO recommendation
Vaccine, meningococcal disease, meningitis, Low- and middle-income countries - Read more

PRESENTED BY TLDR BIOTECH
What would you do with 6.5k+ meticulously tagged biotech & pharma data points?

Over the past year, TLDR Biotech has been collecting and categorizing industry news across approvals, clinical trials, fundraises, partnerships, M&A, politics & policy, and much much more.

Each data point is tagged by drug modality, disease indication, tech area, and even more specific categories. For example:

🔍 Need to track all small molecule fundraises across oncology?

📈 Want a curated list of recent cell therapy clinical trials updates (both the successes and failures)?

💡 Looking for trends in Alzheimer's and Parkinson's disease partnerships?

We’re leveraging this resource to build tailored reports and curated insights for select clients—and we’re opening up limited access to interested parties.

If you’re interested, send us an email [email protected] with the subject line “6K BIOTECH DATA” and we’ll chat further.*

*If you’ve received this newsletter as an email, just hit reply!

THE BAD
Approvals & Labels

Seikagaku received FDA complete response letter for SI-6603 (targeting GAGs), a treatment for lumbar disc herniation, due to manufacturing facility concerns
Enzyme, lumbar disc herniation, complete response letter (CRL), quality concerns - Read more

THE BAD
Clinical Trials

Ascletis Pharma's ASC47 (thyroid hormone receptor β agonist) delivers only showed 1.7% weight loss in Ph1b obesity trial, though argues benefit of slower weight loss
Small molecule, obesity - Read more

THE BAD
Lawsuits

Academics argue Gilead should be held accountable for allegedly intentionally delaying a safer HIV drug's release
Product hopping - Read more [Paywall]

THE UGLY
Public Health

Oklahoma confirms first two measles cases linked to Texas-New Mexico outbreak
Measles, infectious disease outbreak, infectious disease - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here